Scoring Systems for Immunohistochemistry in Urothelial Carcinoma

Bösherz, Mark-Sebastian; Samarska, Iryna; Gaisa, Nadine T.

doi:10.1007/978-1-0716-3291-8_1

Cited by 1 publication

(1 citation statement)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding EGFR interpretation: Negative result was considered if less than 1% of the cells were positive. Then categorization of the cases was done into 3 groups: Low expression (1-10%), Moderate expression (10-50), High expression (more than 50%) [13].…”

Section: Correlation Of the Expression Of Different Markersmentioning

confidence: 99%

Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy

Shalaby,

Mahmoud,

Sayed

et al. 2024

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Introduction: The alterations of EGFR and HER2/neu as growth factor receptors and the cytoplasmic signal transduction proteins of RAS/RAF/MAP kinases including its end effector molecule ( ERK ) are important in the carcinogenesis of many tumors. The activation of these protooncogenes in prostate cancer is still under investigation. The aim of this work was to study EGFR , HER2- neu, inactive (non-phosphorylated) and active (phosphorylated) ERK expression in prostatic adenocarcinomas in correlation to the clinical and pathological parameters. Methods: Immunohistochemistry- using tissue microarrays- for EGFR , HER2/neu , non-phosphorylated, and phosphor- ERK , was performed on tissues from 166 patients- with primary prostatic adenocarcinoma with no prior treatment-. The results of different markers expression were correlated with the clinical and pathological parameters and were analyzed statistically. Results: The prostatic tissue showed EGFR , HER2 neu, phosphorylated and non-phosphorylated ERK expression in 8.4%, 1.4%, 78.2%, and 83.4% respectively whether low (patchy) or high expression (diffuse). There were no significant correlations found between patient characteristics and expression of the tested markers. The negative immune reactivity for non-phosphorylated ERK and EGFR - was significantly correlated with high tumor stage (p values 0.03 and 0.01, respectively). Conclusion: EGFR and HER2/neu may play a limited role in prostatic adenocarcinoma as they showed positive expression in a limited number of the examined tissues specifically HER2neu. The expression of non-phosphorylated ERK (mostly weak to moderate) and phosphorylated ERK (mostly moderate to strong)- was appreciated in most cases. Thus, we suggest that anti- EGFR drugs may have a limited role in the treatment of castrate-resistant prostate cancer, but anti-MEK/ ERK drugs may have more promising role as a target therapy. It is recommended to perform further molecular testing to elucidate the exact mechanism and significance of these markers.

show abstract

Section: Correlation Of the Expression Of Different Markersmentioning

confidence: 99%